Galmed Reveals Early Aramchol Data From Late-Stage NASH Trial

Galmed Pharmaceuticals Ltd GLMD announced results from the first 16 patients in the Open-Label Part of the ARMOR Phase 3 study who underwent a scheduled post-baseline biopsy.
ARMOR is assessing the evaluate the safety and efficacy of Aramchol for the treatment of NASH and fibrosis.
Treatment with Aramchol reduced fibrosis progression in 15 out of the 16 patients.
8 out of the 16 patients (50%) showed fibrosis improvement by more than 1 point.
In 3 patients (19%), fibrosis was reduced by 2 points.
In 7 of 16 (44%) patients, there was fibrosis improvement without worsening of NASH.
Aramchol continues to show good safety and tolerability.
Related Link: Galmed Stock Jumps As FDA Signs Off Use Of Aramchol Meglumine In Late-Stage NASH Trial.
Price Action: GLMD shares are up 12.20% at $2.77 during the market session on the last check Monday.